

H2 Global Group is pioneering a new category in brain health — combining **molecular hydrogen (H₂) therapy** with **VR-based neurorehabilitation** to address key biological mechanisms associated with Alzheimer's disease and dementia. With 139 million people projected to suffer from dementia by 2050 and existing biologics demonstrating limited clinical benefit, we offer a **safe, clinically scalable, and patent-protected platform** already generating revenue across 37+ commercial deployments in Europe. **Cochrane 2026** confirmed no clinically meaningful effect in 20,342 patients across 17 trials — reinforcing a substantial unmet need in Alzheimer's care we are uniquely positioned to address.

139M People with dementia globally by 2050	\$2T+ Global dementia cost projected to exceed \$2T by 2030	<1.5% Patients eligible for current biologics	No SAE Reported In published H ₂ studies to date	~\$44M Revenue Target (~1.0B CZK)
--	---	--	---	---

OUR SOLUTION: H₂ THERAPY PLATFORM

- Built on **19 years of research** led by Prof. Shigeo Ohta, Ph.D. (Nature Medicine, 2007). Backed by **2,000+ publications** and 80+ clinical trials.
- H₂ crosses the **blood-brain barrier** and selectively neutralizes ·OH and ONOO⁻ — targeting oxidative stress and neuroinflammation **associated with neurodegeneration**.
- No serious adverse events** reported in published hydrogen studies to date. No ARIA-related risk reported to date. No immunosuppression. Suitable for the full patient spectrum.
- VR Life synergy (18.26% stake)**: MDR-certified VR neurorehab device. 40+ EU hospitals. 24-50% pain reduction. 3:1 patient-to-therapist ratio. \$650K seed at ~\$1.38M implied valuation.

THE PLATFORM: BEYOND ALZHEIMER'S

- H₂ Therapy**: Addresses oxidative stress and neuroinflammation — key drivers of cellular aging. Applicable across Alzheimer's, Type 2 diabetes, ocular/auricular conditions, wound healing, and sports recovery.
- H₂ Longevity Clinics**: Franchisable clinical wellness model combining H₂ + VR. Scalable across Medical Spas, Sport & Physio, Dental, Veterinary, and Aesthetics sectors.
- Military & First Responders**: Growing interest among military and first responder organizations for physical regeneration and PTSD support — high-value, underserved segment.

CLINICAL VALIDATION

- Ono/Ohta Pilot Study (2023) — Japan**
H₂ inhalation 6 months in Alzheimer's patients.
✓ **Significant ADAS-Cog improvement** · Findings suggest a **potential disease-modifying effect** · Persisted 6 months post-treatment
- Nishimaki RCT (2018) — Japan**
H₂-rich water in APOE4 carriers (highest genetic risk group).
✓ **Improved cognition in highest-risk Alzheimer's population**
- EU Clinical Trial (2026) — Czech Republic · SÚKL Approved**
University Hospital Ostrava · PI: Prof. David Školoudík · 30 patients (MCI to moderate dementia) · 6 months
✓ **Early results appear highly encouraging**

MARKET OPPORTUNITY

\$10.9B Alzheimer's Therapy Market by 2034 · CAGR 8.7%	\$5.0B Global Molecular Hydrogen Market by 2030 · CAGR 15.7%	\$1.87B Premium Longevity Clinics Market by 2034 · premium solutions	46% US Share of Global Medical Device Market FDA pathway underway
---	---	---	--

PROPRIETARY IP PORTFOLIO — 4 GRANTED PATENTS + UTILITY MODELS

Patent / Utility Model	Scope	Jurisdictions
EP 3701956 B1	Prevention & treatment of Alzheimer's dementia	EU (valid to 2037-38)
PCT/JP2023/028004	Disease-modifying drug · long-term effects 6-12 months post-treatment	22 national phases incl. USA, China, Canada
EP 3485892 B1	MCI/dementia in ApoE ε4 allele carriers	EU
US 9,050,278 B2	Reactive oxygen species scavenger in vivo	USA
CZ 37523 U1	H ₂ + VR Integration (synchronized breathing/VR)	Czech Republic

REGULATORY ROADMAP — H₂ MEDICAL DEVICE PLATFORM SOLUTION

2026	2027	2028	2029	2029+
Clinical Trial Completion	CE Mark (EU)	FDA Registration	Asian Market Expansion	Potential Strategic Exit Valuation

\$25-35M Series A Target Raise	~\$80M Pre-Money Valuation	~\$8M → \$44M Revenue 2021-25 → Target	4 Patents EU + US · valid to 2037-38 + 22 national phases	\$500M-1.5B Potential Strategic Exit Valuation
--	--------------------------------------	--	---	--

STRATEGIC EXECUTION

- ✓ Finish clinical trials & R&D.
- ✓ Obtain CE Mark and FDA approvals.
- ✓ Execute US market entry.
- ✓ Scale commercial ops and H₂ Clinics.
- ✓ Restructure and retire existing debt obligations to strengthen the balance sheet and position the company for accelerated growth.

